Health ❯ Medicine ❯ Clinical Trials

Drug Approval

FDA Regulatory Affairs FDA Regulations

GSK to Acquire 35Pharma for $950 Million to Add Pulmonary Hypertension Candidate HS235

The signed deal would place an activin‑pathway therapy with phase 1 data into GSK’s RI&I pipeline pending U.S. and Canadian clearance.

FDA Clears UCLA’s ENPP1-Blocking Antibody AD-NP1 for First-in-Human Trial